Adding a second drug improved tumor response rate and survival rate in advanced non-small cell lung cancer (NSCLC). Adding a third drug had a weaker effect on tumor response and no effect on survival

This review has been withdrawn.

The reason for withdrawal and previous versions are archived and accessible within the withdrawn record in the Cochrane Library.